Wells Fargo & Company Has Lowered Expectations for uniQure (NASDAQ:QURE) Stock Price

uniQure (NASDAQ:QURE) had its price target cut by equities research analysts at Wells Fargo & Company from $35.00 to $30.00 in a research report issued on Friday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective suggests a potential upside of 139.10% from the company’s current price.

Several other research analysts have also commented on the stock. Stifel Nicolaus upped their price objective on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. HC Wainwright upped their price target on uniQure from $25.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, January 27th. Cantor Fitzgerald raised their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. The Goldman Sachs Group boosted their target price on uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. Finally, Leerink Partners raised their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.89.

uniQure Trading Up 4.0 %

Shares of QURE stock traded up $0.48 during trading hours on Friday, reaching $12.55. The company’s stock had a trading volume of 348,751 shares, compared to its average volume of 1,000,732. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The stock has a market capitalization of $611.58 million, a P/E ratio of -2.53 and a beta of 0.38. The firm’s fifty day simple moving average is $15.12 and its 200 day simple moving average is $9.75. uniQure has a one year low of $3.73 and a one year high of $19.18.

Insider Buying and Selling at uniQure

In related news, CFO Christian Klemt sold 2,916 shares of the stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the sale, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now directly owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,915 shares of company stock worth $588,112. Company insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

A number of institutional investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its holdings in shares of uniQure by 49.1% in the third quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock valued at $1,338,000 after purchasing an additional 89,400 shares during the last quarter. abrdn plc increased its stake in shares of uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after acquiring an additional 1,528,581 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 57.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares during the period. Atria Investments Inc purchased a new position in shares of uniQure during the 3rd quarter worth $53,000. Finally, Privium Fund Management B.V. boosted its position in shares of uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock valued at $3,672,000 after acquiring an additional 104,500 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.